Schering-Plough's Isepacin
Executive Summary
Essex Nippon K.K., the company's Japanese subsidiary began marketing of the new aminoglycoside antibiotic in Japan. Isepacin (isepamicin) is approved, in Japan, in both IV and injection form for urinary and respiratory tract infections. Isepacin, which was discovered by Schering Research, will be co-marketed by the joint developers of the drug - Essex Nippon and Toyo Jozo, Ltd. Schering-Plough notes that the drug's safety profile has been established in clinicals of more than 1,000 patients. Isepacin is in clinicals in the U.S.